{"pmid": "12100048", "sentences": {"sent_1": {"Section": "", "text": "METHODS : After a 3 - to 5 - day , single - blind placebo run - in period , 1302 male and female patients ( aged 15 - 81 years ) with active allergic rhinitis symptoms were randomly assigned to receive montelukast 10 mg ( n = 348 ) , loratadine 10 mg ( n = 602 ) , or placebo ( n = 352 ) administered once daily at bedtime for 2 weeks during the spring allergy season .", "entities": {"entity_1": {"text": "male", "class": "Participant", "negation": 0, "UMLS": "", "index": 1, "start": 21}, "entity_2": {"text": "female", "class": "Participant", "negation": 0, "UMLS": "", "index": 2, "start": 23}, "entity_3": {"text": "aged 15 - 81 years", "class": "Participant", "negation": 0, "UMLS": "", "index": 3, "start": 26}, "attribute_1": {"text": "15 - 81 years", "class": "measure", "negation": 0, "UMLS": "", "index": 4, "start": 27}, "entity_4": {"text": "active allergic rhinitis symptoms", "class": "Participant", "negation": 0, "UMLS": "C2607914:allergic rhinitis,C1457887:symptoms,C1320102:Factive,", "index": 5, "start": 33}, "entity_5": {"text": "montelukast 10 mg", "class": "Intervention", "negation": 0, "UMLS": "C0298130:montelukast,", "index": 6, "start": 42}, "attribute_2": {"text": "10 mg", "class": "measure", "negation": 0, "UMLS": "", "index": 7, "start": 43}, "entity_6": {"text": "loratadine 10 mg", "class": "Intervention", "negation": 0, "UMLS": "C0987270:loratadine 10 mg,", "index": 8, "start": 51}, "attribute_3": {"text": "10 mg", "class": "measure", "negation": 0, "UMLS": "", "index": 9, "start": 52}, "entity_7": {"text": "placebo", "class": "Intervention", "negation": 0, "UMLS": "C0032042:placebo,", "index": 10, "start": 61}}, "relations": {}}}}